Prof. Saadettin Kilickap
6
reviews
07/09/2020
25/10/2018
19/10/2018
04/10/2018
03/06/2018
22/11/2017
Professor Saadettin Kilickap is a medical oncologist from Ankara who specializes in the treatment of solid tumors, primarily lung cancer.
He graduated with honors from the Gazi University Faculty of Medicine in 1998, then completed his residency in internal medicine and his sub-specialty in medical oncology at Hacettepe University, becoming a board-certified oncologist in 2009. In the same year he completed the Master’s program in “Cancer Epidemiology” at the Hacettepe University Oncology Institute.
Since 2024, Professor Kilickap has been a member of the Scientific Advisory Board of the American biotechnology company MAIA Biotechnology (NYSE American), which develops targeted immuno-oncology drugs. This appointment is based on his experience as a principal or co-investigator in more than 40 multicenter Phase 2 and Phase 3 clinical trials.
Today he works at Liv Hospital Ankara (part of the MLP Care Group) and teaches at the İstinye University Faculty of Medicine.
Achievements and awards
About Professor Saadettin Kilickap
Medical oncology; focused areas — lung cancer (especially ALK+, EGFR+ non-small cell), breast cancer, melanoma, gastrointestinal tumors; immunotherapy and targeted therapy; cancer epidemiology; quality of life in oncology patients.
- 1998 — Gazi University Faculty of Medicine (with honors), medical degree
- 2003 — specialization in internal medicine, Hacettepe University Faculty of Medicine
- 2009 — sub-specialization in medical oncology, Hacettepe University
- 2009 — Master’s degree in the “Cancer Epidemiology” program, Hacettepe University Oncology Institute.
- Until 2009 — internal medicine and oncology at Hacettepe University
- After 2009 — medical oncology at Hacettepe University.
- Currently — Professor at İstinye University Faculty of Medicine, Department of Medical Oncology; Liv Hospital Ankara.
More than 240 articles in international peer-reviewed journals.
More than 50 poster presentations at international congresses.
Principal or co-investigator in 40+ multicenter clinical trials.
Co-author of national publications by the Turkish Oncology Group, including the key paper “Lung Cancer in Turkey” (J Thorac Oncol, 2022).
- Turkish Medical Oncology Association (TTOD)
- Turkish Internal Medicine Specialist Association
- Academic Geriatrics Association
- Medical Research and Education Association
- National Cancer Advisory Board, Preventive Oncology Subcommittee.
- Turkish Medicines and Medical Devices Agency
- MAIA Biotechnology Scientific Advisory Board (since 2024).
Liv Hospital Ankara is part of the MLP Care Group — one of the largest private medical groups in Turkey, combining 29 years of experience of the Liv Hospital, Medical Park and VM Medical Park brands, as well as the academic base of İstinye University.
Liv Hospital is positioned as the premium-segment clinic of the network, focused on complex cases of oncology, neurosurgery, organ transplantation and robotic surgery. It is one of the major oncology centers in Turkey, offering modern methods of radiation therapy, chemotherapy and nuclear medicine.
For patients in medical oncology, Liv Hospital Ankara offers treatment of common solid tumors — lung, breast, gastrointestinal tract, melanoma; access to modern targeted drugs and immunotherapy; a multidisciplinary approach with radiation and surgical oncologists; modern diagnostic equipment (CT, MRI, PET-CT); an international department for foreign patients.
